The global recombinant follicle-stimulating hormone market is anticipated to grow at a significant CAGR of 2.5% during the forecast period (2022-2028). Female infertility and male hypogonadism are both treated with the recombinant follicle-stimulating hormone. It is prescribed to those women who are troubling during ovulation or who are undergoing reproductive treatments, such as IVF. It also aids the development of sperm cells in men. The market for recombinant follicle-stimulating hormones is primarily driven by rising infertility among men and women. Additionally, rising disposable income and the widespread availability of trained specialists are also supporting the growth of the market. The increasing number of cases of pituitary or hypothalamic diseases necessitates the use of fertility tests. As a result, the follicle-stimulating hormone is included in the fertility test of both males and females.
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-
- In September 2021, Seoul Maria Fertility Hospital of South Korea conducted a prospective cohort study in order to develop a treatment algorithm for controlled ovarian stimulation to select a starting dose of recombinant follicle-stimulating hormone based on patient characteristics and ovarian response.
- In August 2021, Merck Specialties Pvt. Ltd. launched Pergoveris Pen for advanced infertility therapy. The company’s goal with this launch is to meet unmet medical requirements by providing a better, more convenient, and ready-to-use combo treatment option for women with severe follicle-stimulating hormone and luteinizing hormone (LH) deficiencies.
- In January 2020, MerckKGaA announced that the European Commission (EC) has given Marketing Authorization (MA) to its novel GONAL-f (follitropin alfa) 150 IU pen. Merck now has an even broader selection of best-in-class pens to support patients from the start of their reproductive stimulation cycle to the finish, when lower doses are required.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Amoxicillin Market at https://orionmarketreports.com/request-sample/?id=102696&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Teva Pharmaceutical Industries Ltd., Merck KGaA, GeneScience Pharmaceuticals, Shanghai Techwell Biopharmaceutical Co., Ltd., and Gedeon Richter Plc., among others.
A full report is available at: https://orionmarketreports.com/global-recombinant-follicle-stimulating-hormone-market/102696/
Global Recombinant Follicle Stimulating Hormone Market Report by Segment
By Type
- 75IU
- 150IU
- Others
By Application
- Infertility Treatment
- Assisted Reproductive Technology
- Others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
